Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial

Aims  To describe the total cardiovascular burden (cardiovascular morbidity or mortality, revascularization or non‐traumatic amputation) in individuals with screen‐detected diabetes in the ADDITION‐Europe trial and to quantify the impact of the intervention on multiple cardiovascular events over 5 years.

[1]  K. Khunti,et al.  Screening for Type 2 diabetes. Lessons from the ADDITION‐Europe study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[2]  Kamlesh Khunti,et al.  Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial , 2011, The Lancet.

[3]  R. Simmons,et al.  Screening for type 2 diabetes: an update of the evidence , 2010, Diabetes, obesity & metabolism.

[4]  N. Wareham,et al.  Who attends a UK diabetes screening programme? Findings from the ADDITION‐Cambridge study , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[5]  K. Khunti,et al.  Rationale and design of the ADDITION-Leicester study, a systematic screening programme and Randomised Controlled Trial of multi-factorial cardiovascular risk intervention in people with Type 2 Diabetes Mellitus detected by screening , 2010, Trials.

[6]  Heiner Greten,et al.  Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). , 2010, The American journal of cardiology.

[7]  Christina Lindahl,et al.  Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. , 2009, Journal of the American College of Cardiology.

[8]  E. Braunwald,et al.  Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction , 2009, Journal of the American College of Cardiology.

[9]  S. Nissen.  Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach? , 2009, Journal of the American College of Cardiology.

[10]  N. Sattar,et al.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.

[11]  N. Wareham,et al.  The ADDITION-Cambridge trial protocol: a cluster – randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients , 2009, BMC public health.

[12]  R. Stolk,et al.  Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. , 2009, The British journal of general practice : the journal of the Royal College of General Practitioners.

[13]  A. Avogaro,et al.  Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes , 2008, Diabetes Care.

[14]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[15]  E. Antman,et al.  Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial , 2008, European heart journal.

[16]  K. Khunti,et al.  Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study , 2008, Diabetologia.

[17]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[18]  S. Thompson,et al.  Wei, Lin and Weissfeld's marginal analysis of multivariate failure time data , 2007, Statistical methods in medical research.

[19]  Evangelos Kontopantelis,et al.  Pay-for-performance programs in family practices in the United Kingdom. , 2006, The New England journal of medicine.

[20]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[21]  Richard J Cook,et al.  Tests for multivariate recurrent events in the presence of a terminal event. , 2004, Biostatistics.

[22]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[23]  O. Pedersen,et al.  MULTIFACTORIAL INTERVENTION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETES , 2003 .

[24]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[25]  P. Home,et al.  Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose , 2002 .

[26]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[27]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[28]  T Lauritzen,et al.  The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening , 2000, International Journal of Obesity.

[29]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[30]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[31]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[32]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[33]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[34]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[35]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .